Research Article Details
| Article ID: | A25865 |
| PMID: | 21378763 |
| Source: | Am J Gastroenterol |
| Title: | Editorial: Exercise for NAFLD: does intensity matter? |
| Abstract: | Currently, there are no established means for the prevention or treatment of non-alcoholic steatohepatitis (NASH) despite our increasing understanding of nonalcoholic fatty liver disease (NAFLD) pathogenesis implicating insulin resistance (IR) as a key factor and highlighting the central role of lipotoxic liver injury in the development of NASH. Lifestyle interventions aiming at decreasing IR and preventing lipotoxicity, including weight loss, diet, and physical exercise, are in the frontline for NASH patient management. Physical activity may ameliorate IR, maintain weight loss, and improve liver histology in NASH patients. However, there are no recognized criteria for the optimal intensity, duration, or total volume of exercise needed to obtain these beneficial effects. In this issue of the American Journal of Gastroenterology, Kistler and colleagues show that vigorous, but not moderate exercise, nor total duration or volume of physical activity, is related to decreased odds of having NASH or advanced fibrosis. Prospective studies using the objective criteria of physical activity, addressing the role of concurrent weight loss, and assessing individual histological features are needed to further clarify the effects of exercise intensity on NAFLD histology. |
| DOI: | 10.1038/ajg.2010.496 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D080 | Citrulline | Chemical drug | DB00155 | -- | -- | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |